BioSpace

BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs

BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for both Opdivo and Eliquis.

By BioSpace

1 min read
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights